A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function

This is an open-label (both [participants and investigator] know what treatment participants
will receive) and multicenter study. The study consists of 3 phases: a screening phase
(approximately 3 weeks), a treatment phase (from day -2 [2 days before the administration of
study medication] to Day 18), and an end-of-study phase (7 to 10 days after the last dose of
study medication). Approximately 24 participants (participants with mild hepatic impairment,
moderate hepatic impairment, and normal liver function) will receive JNJ-38518168 for 14
days. Hepatic impairment will be evaluated according to Child-Pugh score. It consists of 5
clinical measures (amount of ascites [an abnormal accumulation of fluid in the abdomen],
total bilirubin [mg/dL], albumin [g/dL], international normalized ratio, and degree of
encephalopathy [abnormal functioning of the brain]). Each is scored from 0 (less severity)
to 3 (highest severity). Total Child-Pugh score is the sum of all subscores and is graded
as: mild (5-6 points), moderate (7-9 points), and severe (10-15 points). Safety will be
evaluated by the assessment of adverse events, clinical laboratory tests, vital signs, body
weight, physical examination, and 12-lead electrocardiogram which will be monitored at
various timepoints throughout the study. The total duration of study participation for each
participant is approximately 6 weeks.

Inclusion Criteria:

- Have normal liver function for the normal hepatic function group

- Have mild or moderate liver diseases as defined by the Child-Pugh Classification and
be clinically stable overall for the mild or moderate liver disease groups

- Doses of drugs used to treat other illnesses or conditions related to liver disease
must be stable for at least 4 weeks before the first dose of study medication with
the exception of thyroid replacement hormone, in which case the dose must be stable
for 3 months before the first dose of study medication. Doses of these drugs must
also be stable during the course of the study

- If an illness with a fever occurs within one week of the start of dosing, dosing must
be postponed until the body temperature is normal for at least 72 hours

- Participants must agree to use one of the contraception methods defined in the
protocol

Exclusion criteria:

- Hepatic insufficiency secondary to autoimmune hepatitis or obstructive liver disease

- Allergy to heparin or history of heparin-induced thrombocytopenia

- All participants must have a negative human immunodeficiency virus test. Participants
with normal liver function must test negative for hepatitis B and hepatitis C

- Severe ascites (an abnormal accumulation of fluid in the abdomen) or severe pleural
effusion (fluid around the lungs)